Systemic sclerosis (SSc) is an
autoimmune disease characterized by
fibrosis of the skin and visceral organs and vascular alterations. SSc pathophysiology involves systemic
inflammation and oxidative stress. Because the vanin-1 gene (vnn1) encodes an
enzyme with
pantetheinase activity that converts vasculoprotective
pantethine into profibrotic
pantothenic acid and
pro-oxidant cystamine, we tested this pathway in the pathophysiology of SSc. Activation of the vanin-1/
pantetheinase pathway was investigated in wild-type BALB/c mice with
hypochlorous acid (HOCl)-induced SSc by ELISA and Western blotting. We then evaluated the effects of the inactivation of vnn1 on the development of
fibrosis, endothelial alterations, and immunological activation in mice with HOCl- and
bleomycin-induced SSc. We then explored the vanin-1/
pantetheinase pathway in a cohort of patients with SSc and in controls. In wild-type mice with HOCl-induced SSc, the vanin-1/
pantetheinase pathway was dysregulated, with elevation of vanin-1 activity in skin and high levels of serum
pantothenic acid. Inactivation of the vnn1 gene in vnn1-/- mice with HOCl-induced SSc prevented the development of characteristic features of the disease, including
fibrosis, immunologic abnormalities, and endothelial dysfunction. Remarkably, patients with diffuse SSc also had increased expression of vanin-1 in skin and blood and elevated levels of serum
pantothenic acid that correlated with the severity of the disease. Our data demonstrate that vanin-1/
pantetheinase controls
fibrosis, vasculopathy, autoimmunity, and oxidative stress in SSc. The levels of vanin-1 expression and
pantothenic acid determine SSc severity and can be used as markers of disease severity. More importantly, inhibition of vanin-1 can open new therapeutic approaches in SSc.